Adverse Event Reports Hit All-Time High; FDA Warns Firms About MDRs, Complaint Handling
• By Shawn M. Schmitt
As FDA sifts through almost a million Medical Device Reports submitted by manufacturers last year, the agency is trying to determine why so many adverse events are being reported. Isaac Chang, a director in CDRH’s Office of Surveillance and Biometrics, speculates that there could be a number of reasons for the large influx of MDRs, including high-profile recalls and a sharper FDA focus on human factors issues. Further, more than half of adverse events were reported to the agency on individual MedWatch forms in 2012 – a sharp increase over previous years. However, despite the extraordinary rise in reports, some firms continue to have trouble developing MDR procedures. Industry experts also weigh in on social media’s impact on adverse event reporting, and tips are shared for ensuring that complaints are properly handled by manufacturers.
Although nearly 1 million adverse events were reported to FDA via its Medical Device Reporting system last year, the agency is consistently warning manufacturers for failing to have adequate MDR procedures in place.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
The US FDA continues to issue early alerts as part of its communications pilot aimed at improving how the agency manages recalls. This time, the agency is notifying users about two separate intravascular catheters.
The US Medicare agency will hold three public meetings in June and July addressing tremor treatment devices and clinical diagnostic lab tests. The first meeting on June 25 will focus on endpoints for Parkinson’s device trials, while subsequent meetings will address payment rates and codes for laboratory tests.
